| Bioactivity | Atracurium (BW-33A) besylate is a potent, competitive and non-depolarizing neuromuscular blocking agent. Atracurium besylate also is an AChR receptor antagonist. Atracurium besylate induces bronchoconstriction and neuromuscular blockade. Atracurium besylate promotes astroglial differentiation[1][2][3][4][5]. |
| Invitro | Atracurium besylate (10 µM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells[4].Atracurium besylate (10 µM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs[4].Atracurium besylate (2.4 µM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells[5]. Cell Proliferation Assay[4] Cell Line: |
| In Vivo | Atracurium besylate (1, 5, 10, 20, 50 mg/kg; i.v.) induces bronchoconstriction in DBA/2 and SJL mice[2].Atracurium besylate (4.8 mg/kg; i.v.) induces neuromuscular blockade in rats[3]. Animal Model: |
| Name | Atracurium besylate |
| CAS | 64228-81-5 |
| Formula | C65H82N2O18S2 |
| Molar Mass | 1243.48 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Basta SJ, et al. Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61(9):723-9. [2]. Levitt RC, et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151(5):1537-42. [3]. Mayer B, et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18(9):599-604. [4]. Spina R, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7(1):459-72. [5]. Nascimento DC, et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):9-14. |
Atracurium besylate
CAS: 64228-81-5 F: C65H82N2O18S2 W: 1243.48
Atracurium (BW-33A) besylate is a potent, competitive and non-depolarizing neuromuscular blocking agent. Atracurium besy
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.